Tucker Carlson’s nicotine pouch brand, ALP Pouch, has positioned itself as bold, rebellious, and anti-establishment. But behind the memes, mockery, including saying on Theo Von’s show that users of the competitor product Zyn take it rectally, is a federally regulated nicotine product navigating one of the most consequential approval processes in the country.
Based on publicly available evidence, the marketing strategy embraced by Tucker Qatarlson may be creating serious regulatory exposure at the worst possible time.
I’ve continually exposed Tucker Carlson as a fraud and a fake MAGA mouthpiece who many believe is funded by Qatar based off of his hostility toward Jews and his business engagements and speeches in several Middle Eastern countries. In addition to spending time in hostile Muslim countries, Tucker has recently been praised by state owned networks in Qatar, Saudi Arabia, Iran and Russia, leading many people to ask how Tucker has not yet been charged with FARA violations.
Tucker’s rhetoric abroad contradicts his “America First” branding at home, including his recent appearance at two Islamic conferences in Qatar and Saudi Arabia alongside Hillary Clinton.
Tucker Qatarlson is not aligned with the MAGA movement and his ALP Pouch business venture provides more evidence showing he’s only in it to make money after being fired, or having his show canceled, by every TV network he’s worked for (Fox News, CNN, and MSNBC).
ALP Pouch was launched in partnership with Turning Point Brands (no affiliation with Turning Point USA), which handles manufacturing and distribution. The company is currently seeking authorization through the FDA’s Premarket Tobacco Product Application (PMTA) process, a rigorous regulatory pathway that requires proof that a product is “appropriate for the protection of public health” (APPH) under 21 U.S.C. § 387 j.
In September 2025, the FDA initiated a pilot program designed to fast-track PMTA decisions for select nicotine pouch brands, including those manufactured by Turning Point Brands. The program was launched amid political pressure to clear regulatory backlogs. But expedited review does not mean exemption from federal tobacco laws.
The statutory requirements remain fully in effect. Under 21 CFR § 1143.3, all advertisements for covered tobacco products, including nicotine pouches, must prominently display the warning:
“WARNING: This product contains nicotine. Nicotine is an addictive chemical.”
For visual advertisements, the warning must occupy at least 20% of the advertisement and comply with strict formatting requirements. Yet, a review of ALP’s official X account (@alppouch) shows multiple promotional posts featuring product imagery and calls to purchase the product that do not display the required nicotine warning.
One September 30, 2025 post depicts U.S. Health and Human Services Secretary Robert F. Kennedy Jr. alongside the caption: “He uses ALP. You should, too.” No warning label appears in the post.
Not only is the required nicotine warning absent, but the post appears to imply endorsement of the product by a sitting HHS Secretary, the department that oversees the FDA itself.
In additional X posts, ALP insinuated that FBI Director Kash Patel, GOP Senator Bill Hagerty, and even President Trump had endorsed their nicotine product. President Trump is notorious for being anti-smoking and anti-tobacco. In all of these posts, there were no visible tobacco warnings for the ALP advertisements on social media, which is required by the FDA.
Under 21 U.S.C. § 387c, tobacco products may be deemed misbranded if their advertising is false or misleading. Federal regulators do not endorse nicotine products. Suggesting such endorsement during a live PMTA review is, at a minimum, legally risky.
Turning Point Brands is not unfamiliar with FDA scrutiny. In 2024, the company received a warning letter concerning its VaporFi products over advertising deficiencies. In 2021, the FDA issued Marketing Denial Orders (MDOs) for certain vapor products, later rescinded after legal challenges. Compliance has been a recurring friction point for Turning Point Brands, the manufacturer of ALP.
And now, during an expedited pilot review, similar issues appear to be resurfacing. Under 21 U.S.C. § 387j(c)(2), the FDA may consider all post-submission information when evaluating whether a product satisfies the APPH standard. That includes social media marketing conducted after the PMTA is filed.
ALP’s strategy has leaned heavily into provocation and personal attacks, including targeted harassment against me as well as Jewish Americans.
On January 25, 2026, the brand promoted a discount code “LarryLoomer,” combining product sales with mockery and misgendering, to suggest that I was born a biological male. In addition to spreading the lie that I was born as a male and calling me “Loony”, suggesting without any medical evidence that I am mentally ill, ALP also posted digitally altered photoshop photos of my face on their social media pages to promote their product. They do not have permission to use my image, name or likeness, and they are violating FDA rules by using fake images of me to promote their nicotine pouches. The tactic mirrors the same performative outrage culture and misinformation tactics Carlson cultivates in his media persona.
ALP has a pattern of targeting Jewish Americans. In another X post from November 2025, ALP listed a promo code attacking Jewish conservative commentator Ben Shapiro, “NoToBenShapiro,” because Shapiro is pro-Israel and called out Tucker Carlson for his anti-Jewish rhetoric and his amplification of anti-Israel conspiracy theories while speaking at AmFest, a political conference hosted by Turning Point USA.
Tucker’s rhetoric frequently departs from verifiable facts, which is why he just issued an apology for falsely claiming Israeli President Isaac Herzog visited Epstein Island in his infamous sit-down with U.S. Ambassador Mike Huckabee.
However, when that same controversy-driven strategy is applied to a regulated nicotine product, regulators are allowed to ask whether it increases misuse risk or appeals to unintended demographics, particularly young people, a top FDA enforcement priority.
On December 5, 2025, ALP reposted and endorsed content from disgraced former Congresswoman Marjorie Traitor Greene falsely accusing me of being a foreign agent for Israel. The allegation is baseless, but it has put my very life at risk amid escalating threats against me. In November, a man was extradited from Texas and arrested and jailed in Palm Beach, Florida for plotting to murder me after he was radicalized online into believing that I am a foreign agent.
ALP may also be violating FDA regulations on product promotion by associating its brand with anti-Semitic harassment, as evidenced by their public suggestion to sponsor YouTube creator Tyler Oliveira, who recently released a video titled “I exposed New Jersey’s Jewish invasion” in which he harassed Jewish residents in a Lakewood, New Jersey community, accusing them of being “invaders” despite their status as US citizens. This potential sponsorship, proposed amid Oliveira’s apparent Patreon ban for “hate”, could be interpreted as indirectly promoting nicotine products through controversial and discriminatory content, potentially breaching FDA guidelines that prohibit misleading, unethical, or improper advertising practices for tobacco-related products. This fits a broader pattern in which Carlson mainstreams content creators obsessed with Jewish topics while insisting his focus is solely on criticizing Israel. Given the Trump administrations’ commitment to Civil Rights enforcement and combatting anti-Semitism, ALP promoting conspiracy theories that target Jewish Americans prompts renewed scrutiny of the FDA’s reported special relationship with ALP, and it calls for reevaluation of any such association.
Amplifying inflammatory accusations while promoting a regulated nicotine product is not just reckless, it may expose the company to additional scrutiny and possibly harm consumers.
FDA-regulated entities are not anonymous meme accounts. They are subject to federal oversight. Leveraging antisemitic dog whistles, divisive rhetoric, and defamatory smears to drive engagement could invite scrutiny under both the Federal Food, Drug, and Cosmetic Act and potentially the Federal Trade Commission’s authority under 15 U.S.C. § 45 governing unfair or deceptive practices.
There are also concerns regarding claims of U.S.-based manufacturing tied to ALP, including references to a linked “Grokipedia” page for ALP that have been flagged as inaccurate. If public marketing claims deviate from what was submitted in the PMTA, that discrepancy alone may raise misbranding concerns under 21 U.S.C. § 387c.
Turning Point Brands’ inclusion in the FDA’s nicotine pouch pilot program places ALP alongside major industry players such as Philip Morris International and R.J. Reynolds. The FDA has issued more than 1,000 Marketing Denial Orders for flavored vape products that failed to meet youth-protection standards. The agency has made clear that compliance with advertising and labeling requirements is mandatory and non-negotiable.
Most major nicotine pouch competitors, including ZYN and On!, prominently embed required nicotine warnings in digital promotions and avoid unsubstantiated claims, adhering to 21 CFR § 1143.3 and 21 U.S.C. § 387k. ALP’s approach appears materially different, relying on controversy-driven engagement during an active federal review.
Tucker seems to avoid accountability for his political shenanigans due to his many political connections inside the Trump administration and the fact that his son Buckley Carlson is currently employed in the White House where he works as the Deputy Press Secretary for Vice President JD Vance. That same nonchalant attitude and disregard for rules and regulations expressed by Tucker Carlson and Turning Point Brands seems to apply to their handling of ALP, an FDA-regulated product deeply related to matters of health and the public interest. Celebrity status and media power do not override federal tobacco laws.
ALP’s is a test case for streamlined approval, launched amid political pressure to clear backlogs by the end of the year. But critics argue it shouldn’t excuse potential violations.
If regulators determine that ALP’s practices constitute misbranding under 21 U.S.C. § 387c or undermine the APPH standard under 21 U.S.C. § 387j, consequences could include civil penalties, import alerts, denial of marketing authorization, or removal from the market.
This is not about memes. It’s about whether Tucker Carlson believes that the rules apply to everyone except him. It’s about whether or not the Trump administration, and particularly Human Health Services (HHS) Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Martin Makary will hold Tucker Carlson and Turning Point Brands accountable for these alleged FDA violations by ALP that could put the general American public at risk.
I have formally submitted a detailed complaint to the FDA’s Center for Tobacco Products outlining potential violations by ALP Pouch and Turning Point Brands. The submission includes supporting documentation and a completed Form FDA 3779 requesting investigation under the Federal Food, Drug, and Cosmetic Act.
The question is: Will the FDA enforce the law evenly, regardless of celebrity, political influence, or media clout? Or will this expedited approval experiment expose a regulatory double standard which will result in a massive financial gain for Tucker Carlson and Turning Point Brands?
The credibility of the PMTA process depends on the answer.
This time, Tucker may not be able to avoid accountability for his, and his company’s, potentially harmful actions and misinformation.
